

**Peer – Reviewed Publications:**

1. **McDonald K**, Hutchinson M, Bresnihan B: The frequent occurrence of neurological disease in patients with late-onset systemic lupus erythematosus. British Journal of Rheumatology 1984;23:186-9.
2. Fitzgerald O, Hanly J, Callan A, **McDonald K**, Molony J, Bresnihan B: Effects of joint lavage on knee synovitis in rheumatoid arthritis. British Journal of Rheumatology 1985;24: 6-10.
3. **McDonald K**, McWilliams E, O’Keeffe B, Maurer B: Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy. European Heart Journal 1988; 9: 893-98.
4. **McDonald K**, Maurer B: Familial aortic valve disease: Evidence for a genetic influence? European Heart Journal 1989;10: 676-77
5. **McDonald K**, Rector TS, Braunlin EA, Kubo SH, Olivari MT: Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. American Journal of Cardiology 1989; 64: 359-63.
6. **McDonald K**, O’Sullivan JJ, McWilliams E, Conroy R, Maurer B: Acute and long term hemodynamic response to low dose enoximone in refractory heart failure. Cardiovascular Drugs and Therapy 1989; 3: 913-918.
7. **McDonald K**, O’Sullivan JJ, Robinson K, Conroy R, Mulcahy R, Maurer B: Heart block as a predictor of in-hospital death in both acute inferior and anterior myocardial infarctions. Quarterly Journal of Medicine 1990; 74: 7277-283.
8. Olivari MT, **McDonald K**, Rector TS: Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am J Cardiol 1990; 66: 1025-1026.
9. **McDonald K**, Francis GS: Angiotensin converting enzyme inhibitor therapy in congestive cardiac failure. ACE report 1990; 69: 1-5.
10. O’Sullivan JJ, **McDonald K**, Erwin J, Crean P, Maurer BJ: Cardiac catheterisation using 5 French catheters. Br Heart J 1990; 64: 211-3.
11. **McDonald KM**, Carlyle PF, Mathews J, Hauer K, Elbers T, Hunter D, Cohn JN: Early ventricular remodelling after myocardial damage and its attenuation by converting enzyme inhibition. Trans Assoc Am Phys 1990;103: 229-235.

12. **McDonald** K; Sanchez de la Pena S; Cavallini M; Olivari MT. Cohn JN; Halberg F. Chronobiologic blood pressure and heart rate assessment of patients with heart transplants. *Prog Clin Biol Res.* 1990;341B:471:80
13. **McDonald** K, Sanchez de la Pena S, Olivari MT, et al: Chronobiologic blood pressure and heart rate assessment of patients with heart transplants. In: *Chronobiology: Its role in clinical medicine, General biology and Agriculture, Part B.* (Pub: Wiley-Liss), 1990: 471-480.
14. Francis GS, **McDonald** KM: Catecholamines and congestive cardiac failure. In: *Catecholamines and Heart Disease.* Ganguly (ed). CRC Press 1991; 87-103.
15. **McDonald** KM, Francis GS: Vasodilator therapy, ACE inhibition and nitrate tolerance. In: *Current Opinion in Cardiology* 1991; 6: 358-362.
16. Cohn JN, Finkelstein S, Kubo SH, McVeigh G, **McDonald** KM, Burns DR, Carlyle PF: Vascular compliance in heart failure, a contribution to impedance and the response to vasodilator drugs. In: Lewis BS, Kimichi A, eds; *Heart Failure. Mechanisms and Management.* Springer-Verlag, 1991.
17. **McDonald** KM, Francis GS: Medical management and review of current trials in heart failure. In: *Congestive heart failure.* Ed: A. Cortina. Prous Science Publ 1991; 81-102
18. **McDonald** K, Francis GS: Clinical problems in cardiopulmonary disease. *Chest* 1991; 99: 1012-1015.
19. Nakleh RE, Copenhauer CM, Werden K, **McDonald** K, Strickler JG: Lack of evidence for involvement of Epstein-Barr virus in the development of the "quilty" lesion of transplanted heart. An in-situ hybridisation study. *J Heart and Lung transplant* 1991;10:504-507.
20. **McDonald** KM, Francis GS: Syndromes of acute left ventricular failure. *J Int Care Med* 1991; 6: 1-11.
21. McVeigh GE, Burns DE, Finkelstein SM, **McDonald** KM, Mock JM, Feske WF, Carlyle PF, Flack JF, Brimm R, Cohn JN: Reduced vascular compliance as a marker for arterial hypertension. *Am J Hypertension* 1991; 4: 245-251.
22. Swift Trial Study Group: Swift trial of delayed elective intervention in conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. *Br Med J* 1991; 302: 555-560.
23. **McDonald** KM, Maurer BJ: Permanent pacing as a treatment for hypertrophic cardiomyopathy. *Am J Cardiol* 1991; 68: 108-110.
24. Johnson TH, **McDonald**, KM, Nakleh R, McGinn AL, Wilson RD, Olivari MT, Kubo SH: Allograft vasculopathy and death in a cardiac transplant recipient with angiographically normal coronary arteries. *Catheterisation and Cardiovascular Diagnosis* 1991; 4: 37-40.
25. O'Sullivan JJ, Conroy RM, **McDonald** KM, McKenna TJ, Maurer BJ: Silent ischaemia in diabetic men with autonomic neuropathy. *Br Heart J* 1991; 66: 303-315.

26. **McDonald** KM, Francis GS, Carlyle PF, Hauer K, Matthews J, Hunter DW, Cohn JN: Hemodynamic, left ventricular structural and humoral changes after discrete myocardial damage in the dog. *J Am Coll Cardiol* 1992; 19: 460-467.
27. Nakleh RE, Kubo SK, Olivari MT, **McDonald** KM: Persistent histologic evidence of rejection in a cardiac transplant recipient. *J Heart and Lung Transplant* 1992; 11: 37-41.
28. **McDonald** KM, Francis GS: The role of vasodilators in heart failure. *Internal Medicine* 1992; 13: 39-47.
29. **McDonald** KM, Francis GS: Recent advances in the use of ACE inhibitors. *Contemporary Internal Med* 1992; 13: 35-46.
30. **McDonald** KM, Francis GS: Epidemiology of congestive heart failure and results of recent drug intervention studies. *Current Opinion in Cardiology* 1992; 7: 397-403.
31. Francis GS, **McDonald** KM: Left Ventricular Hypertrophy: An initial response to myocardial injury. *Am J Cardiol* 1992; 69: 3G-9G.
32. **McDonald** KM, Parrish T, Wennberg P, Stillman A, Francis GS, Cohn JN, Hunter DN: Rapid, accurate and simultaneous non-invasive assessment of right and left ventricular mass using high speed magnetic resonance imaging. *J Am Coll Cardiol* 1992; 19: 1601-1607.
33. Garr MD, **McDonald** KM, Francis GS: Neurohormonal activation and its relationship to the early stages of left ventricular dysfunction. *Heart Failure* 1992; 8: 167-176.
34. **McDonald** KM, Cohn JN: Left ventricular mass and volume after myocardial infarction. *J. Am Coll Cardiol* 1993; 22: 2059-2060.
35. **McDonald** KM, Francis GS, Matthews J, Hunter DW, Cohn JN: Chronic oral nitrate therapy prevents long-term ventricular remodelling in the dog. *J Am Coll Cardiol* 1993; 21: 514-522.
36. Francis GS, **McDonald** KM, Cohn JN: Neurohormonal activation in pre-clinical heart failure: Remodelling and the potential for intervention. *Circulation* 1993; 87 (supplV): 90-96.
37. **McDonald** KM, Zhang J, Uoshiawa M, Francis GS, Ugurbil K, Cohn JN: Myocardial bioenergetics abnormalities in canine asymptomatic left ventricular dysfunction. *J Am Coll Cardiol* 1994; 23:3: 786-793.
38. **McDonald** KM: The patent infarct – related artery after myocardial infarction. *Circulation* 1994; 90: 1110 –1112.
39. Yuk DD, Shumway S, Kubo SH, Francis GS, Bank AJ, **McDonald** KM, Jesserum J, Verfaillie C: Primary cardiac lymphoma treated with cardiac transplantation. A case report. *J Heart Lung Trans* 1994; 13: 538-542.
40. **McDonald** KM, Garr M, Carlyle PF, Francis GS, Hauer K, Hunter DW, Parrish T, Stillman A, Cohn JN: Relative effects of alpha adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodelling in the dog. *Circulation* 1994; 90: 3034-3046.

41. **McDonald** KM, Rector T, Carlyle PF, Francis GS, Cohn JN: Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodelling in a canine model of discrete myocardial damage. *J Am Coll Cardiol* 1994; 24: 1762-1768.
42. Francis GS; **McDonald** K, Chu C, Chon JN. Pathophysiologic aspects of end stage heart failure. *Am J Cardiology* 1995 Jan 19;75(3):11A-16A.
43. **McDonald** K: Anti-remodeling affects of ACE inhibitors. *Coronary Artery Disease* 1995; 6: 295-301.
44. **McDonald**, Mock J, D'Aloia A. Parrish T, Hauer K, Francis G, Stillman A, Cohn JN: Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. *Circulation* 1995; 91: 2043-2048.
45. Rector TS, Tschumperlin LK, Bank AJ, Francis GS, **McDonald** K, Keeler CA, Silver MA: Use of the Living with Heart Failure Questionnaire to ascertain patients' perspectives on worthwhile improvement in quality of life and risk of drug-induced death. *Journal of Cardiac Failure* 1995; 1: 3: 201-206.
46. Zhang J, **McDonald** KM. Bioenergetic consequences of left ventricular remodeling. *Circulation* 1995; Aug 15;92(4):1011-9
47. Carlyle WC, Toher CA, Vandervelde JR, **McDonald** KM, Homans DC, Cohn JN: Changes in  $\beta$ -actin mRNA expression in remodelling canine myocardium. *J. Mol Cell Cardiol* 1996; 28: 58-63.
48. Carlyle WC, Jacobson A, Judd D, Toher CT, Hauer K, Hartman M, **McDonald** KM: Delayed reperfusion alters matrix metalloproteinase activity and fibronectin mRNA expression in the infarct zone of the ligated rat heart. *J Mol Cell Cardiol* 1997; 29: 2451-2464.
49. Wilke J-HM, Wang Y, Huang Y, Christensen BV, Stillman AE, Ugurbil K, **McDonald** KM, Wilson RF: Myocardial perfusion reserve: assessment with multisection, quantitative first pass MR imaging. *Radiology* 1997; 204: 373-384
50. **McDonald** KM, Chu C, Francis GS, Judd D, Carlyle WC, Toher C, Hauer K, Hartman M: The effect of delayed reperfusion following infarction in the rat on structural changes in viable myocardium. *Cardiovasc Res* 1997; 36: 347-353.
51. **McDonald** KM, Chu C, Francis GS, Carlyle WC, Judd DL, Hauer K, Hartman M, Cohn JN: Effect of delayed intervention with ACE inhibitor therapy on myocyte hypertrophy and growth of the cardiac interstitium in the rat model of myocardial infarction. *J Mol Cell Cardiol* 1997; 29: 3203-3210.
52. Francis GS, **McDonald** KM: Overview of survival studies in left ventricular dysfunction. In: *The Clinicians Guide to ACE inhibition*. JG Cleland (ed). Churchill Livingstone 1993; 150-163.
53. Francis GS, **McDonald** KM: Congestive heart failure: Mechanisms, physiologic derangements and therapy. In: *Cardiovascular Pharmacology and Therapeutics*. Singh BN, Dzau VJ, Vanhoutte P, Woosley RL (eds). Churchill Livingstone, Inc. 1993; pp 765-779.
54. Francis GS, **McDonald** KM. Neurohumoral activation in preclinical heart failure. Remodelling and the potential for intervention. *Circulation* 1993; 87 (Supp IV): 90-96.

55. **McDonald** KM, Francis GS: Neuroendocrine activation in heart failure. In: Pouleur H, Barnett D, Francis G (eds) Congestive Cardiac Failure. Pathophysiology and Treatment. New York, Basel, Hong Kong, Marcel Decker 1993; pp 49-70.
56. Francis GS, **McDonald** KM: Neurohumoral mechanisms in heart failure. In: Heart Failure, 90-116. S. Rahimtoola D, McCall (eds): Chapman and Hall 1995.
57. Francis GS, **McDonald** KM, Chu C, Cohn JN: Pathophysiological aspects of end-stage heart failure. American Journal of Cardiology 1995; 75: 11A-16A.
58. **McDonald** KM: Regression of established ventricular remodelling. Heart Failure Review 1996; 1: 131-137.
59. **McDonald** KM, Francis GS: Pharmacological interventions in experimental remodelling: ACE inhibition and AT1 receptor blockade. In: The Failing Heart NS Dhalla, RE Beamish, M Nagano, Editors. Raven Press. 1997; 173-187.
60. **McDonald** KM, Maurer BJ. The Network Study. Eur. Heart Journal 1998; 19: 1740-2.
61. **McDonald** KM: Prevention of ventricular remodelling. J Lab Clin Med 1998; 131: 124-129.
62. Braunllin EA, Olivari MT, **McDonald** KM, et al. Usefulness of surveillance endomyocardial biopsy after paediatric cardiac transplantation. Clin. Transplant 1998; 12: 184-9.
63. **McDonald** KM, Stillman AS, Francis GS, Cohn JN: Functional impact of an increase in ventricular mass after myocardial damage and its attenuation by converting enzyme inhibition. J Card Failure 1998; 4: 203-12.
64. Tian B, Carlyle WC, **McDonald** KM, Judd DL, Francis GS, Cohn JN: Localisation of changes in  $\beta$ -actin expression in remodelled canine myocardium. J Mol Cell Cardiol 1999; 4: 751-760.
65. Shanahan EM, Sheahan K, **McDonald** K, Bresnihan B. [Dilated cardiomyopathy in Wegener's granulomatosis](#). Rheumatology (Oxford). 1999 Nov;38(11):1164-6
66. ran M, Barrett F, Mulqueen M, Begley F, Quigley P, Maurer B, **McDonald** KM: Basics of heart failure management: Are they being ignored? European Journal of Heart Failure. European Journal of Heart Failure 2000; 2: 101-105.
67. **McDonald** KM, Ledwidge M, Cahill J, Kelly J, Quigley P, Maurer B, Begley F, Ryder M, Travers B, Timmons L, Burke T: Elimination of early rehospitalisation in a randomised controlled trial of multidisciplinary care in a high risk, elderly heart failure population. European Journal of Heart Failure 2001; 3: 209-215.
68. ill JC, Ryan E, **McDonald** KM. Doppler-echocardiographic analysis of sequential heart failure admissions with preserved left ventricular function. European Journal of Heart Failure 2002;4:473-478

69. McDonald KM, Ledwidge M, Cahill J, Ryan E, Ryder M, Travers B, Timmons L, McNally C, Walsh A. Heart failure management: multidisciplinary care has intrinsic benefit above the optimization of medical care. *Journal of Cardiac Failure* 2002;8(3): 142-148.
70. Cahill JM, Horan M, Quigley P, Maurer B, **McDonald** K. [Doppler-echocardiographic indices of diastolic function in heart failure admissions with preserved left ventricular systolic function.](#) *Eur J Heart Fail.* 2002 Aug;4(4):473-8.
71. **McDonald** KM, Ledwidge KL. Heart Failure Management Programs: Can we afford to ignore the Inpatient phase of care? *Journal of Cardiac Failure* 2003; 9: 4: 258-262
72. Ledwidge M, Barry M, Cahill J, Ryan E, Ryder M, Travers B, Kieran E, Timmons L, Quigley P, Maurer B, **McDonald** KM. Is multidisciplinary care of heart failure cost effective when combined with optimal medical care? *European Journal of Heart Failure* 2003; Volume 5; 381-389.
73. Ryder M., Travers B., Timmons L., Ledwidge M., **McDonald** K. Specialist nurse supervised in-hospital titration to target dose ACE inhibitor – is it safe and feasible in a community heart failure population? *European Journal of Cardiovascular Nursing*, 2003; 2: 183-188.
74. Ryder M; Travers B; Ledwidge M; **McDonald** K. Multidisciplinary care of heart failure: what have we learned and where can we improve? *European Journal of Cardiovascular Nursing*, 2003; 2: 247 – 249.
75. Ryan E, Devlin M, Prendiville T, Ledwidge M, **McDonald** K. The prevalence and natural history of anaemia in an optimally treated heart failure population. *Br J of Cardiol.* 2004: 11: 369 – 375.
76. Ledwidge M, Travers B, Ryder, Ryan E, **McDonald** KM. Specialist care of heart failure improves appropriate pharmacotherapy at the expense of greater polypharmacy and drug-interactions. *Eur J Heart Failure*, 2004 Vol 6(2); 235-243.
77. Ledwidge M, Ryan E, O'Loughlin C, Ryder M, Travers B, Kiernan E, Walsh A, **McDonald** K. Heart Failure care in a hospital unit: a comparison of standard 3-month and extended 6-month programs. *Eur J Heart Failure.* 2005: 7(3):385-91.
78. **McDonald** K. Current Guidelines in the management of chronic heart failure: practical issues in their application to the community population. *Eur J Heart Failure.* 2005;7(3): 317-21.
79. M. Ledwidge, K. **McDonald**. Prevention of heart failure: further insight from BNP. *Br. J Cardiology.* 2005: 12 (3): 175 – 177
80. Lewin J, Ledwidge M, O'Loughlin C, McNally C, **McDonald** K. Clinical Deterioration in Established Heart Failure: What is the value of BNP and Weight Gain in Aiding Diagnosis? *Eur J Heart Failure* 2005. 7: 953 – 957
81. Cahill JM, Ryan E, Travers B, Ryder M, Ledwidge M, **McDonald** K. [Progression of preserved systolic function heart failure to systolic dysfunction -- a natural history study.](#) *Int J Cardiol.* 2006 Jan 4;106(1):95-102.

82. Conlon C, O'Loughlin C, Ledwidge M, **McDonald** K. Community direct access service for early detection and treatment of clinical deterioration: Effectiveness and Impact on the work load pattern of a hospital based heart failure unit. *Disease Management Health outcomes*. 2006; 14: 3: 185 – 190.
83. Karrupiah S, Graham F, Ledwidge M, Conlon C, Cahill J, O'Loughlin C, McManus J, **McDonald** K. Elevated BNP with normal systolic function in individuals at-risk for Heart Failure: a marker of diastolic dysfunction and clinical risk. *Irish Journal of Medical Science* 2006. 175: 4: 5 - 13.
84. Ken **McDonald** & Niamh Murphy. An ageing population and increased MI survival rates are contributing to the increased prevalence of heart failure. *Cardiology Professional*. 2006. Vol 1(2) pg 21 – 24.
85. Cahill J, Ryan E, Travers B, Ryder M, Ledwidge M, **McDonald** K. Progression of Preserved systolic function to systolic dysfunction – a natural history study. *Int J of Cardiology*. 2006 Jan 4; 106(1): 95–120.
86. Ponikowski P, Anker S, Szachniewicz J, Okonko D, Ledwidge M, Zymlinski R, Ryan E, Wasserman S, Baker Nigel, Rosser D, Rosen S, Poole-Wilson P, Banasiak W, Coats A, **McDonald** K. Effect of Darbepoetin alfa on exercise tolerance in anaemic patients with symptomatic Chronic Heart Failure: a randomized, Double-Blind, Placebo-controlled trial. *J Am Coll Cardiol*. 2007. 49:7: 753 – 762.
87. **McDonald** K, Conlon C, Ledwidge M. Disease management programs for heart Failure: Not just for the 'sick' heart failure population. *Eur J Heart Fail*. 2007. 9: 113 – 117.
88. Travers B, O'Loughlin C, Murphy N.F., Ryder M, Conlon C, Ledwidge M, **McDonald** K. Fluid restriction in the management of decompensated heart failure: no impact on time to clinical stability. *J Card Failure* 2007. 13: 2: 128 – 132.
89. O'Hanlon R, O'Shea P, Ledwidge M, O'Loughlin C, Lange S, Conlon C, Phelan D, Cunningham S, **McDonald** K. J. The biological variability of B-type natriuretic peptide and N-Terminal pro-B-type natriuretic peptide in stable heart failure patients. *J. Card Failure* 2007. 13: 1: 50 - 55
90. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Conlon C, Patle A, Donnelly S, **McDonald** K. Diastolic Heart Failure: Evidence of increased myocardial collagen turnover linked to diastolic dysfunction. *Circulation* 2007 Feb 20;115(7):888-95. PubMed PMID: 17283265
91. Murphy N, Mockler M, Ryder M, Ledwidge M, **McDonald** K. Decomposition of chronic Heart Failure associated with Pregabalin in patients with neuropathic pain. *J Cardiac Failure*. 2007. 13: 3: 227-229.
92. **McDonald** K. Disease management of chronic Heart Failure in the elderly: Issues and opinions. *Disease Management and Health Outcomes Journal*: 2007 - Volume 15 - Issue 6 - pp 333-339
93. O'Hanlon R, O'Shea P, Ledwidge M, O'Loughlin C, Lange S, Conlon C, Phelan D, Cunningham S, **McDonald** K. J. The biological variability of B-type natriuretic peptide and N-Terminal pro-B-type natriuretic peptide in stable heart failure patients. *J. Card Failure* 2007 Feb 13(1): 50 - 55

94. Murphy N.F., **McDonald** K. Treatment of anaemia in Chronic Heart Failure – Optimal approach still unclear. *Eur Heart J*. 2007 Sep; 28(18):2185-7 (Epub 2007 Aug 17).
95. Murphy N.F., O'Loughlin C, Ledwidge M, McCaffrey D, **McDonald** K. Improvement but no cure of left ventricular systolic dysfunction in treated heart failure patients. [Eur J Heart Fail](#). 2007 Dec;9(12):1196-204.
96. Ryder M, Murphy NF, McCaffrey D, O'Loughlin C, Ledwidge M, **McDonald** K. [Outpatient intravenous diuretic therapy; potential for marked reduction in hospitalisations for acute decompensated heart failure](#). *Eur J Heart Fail*. 2008 Mar;10(3):267-72. Epub 2008 Mar 4
97. **McDonald** K. Diastolic Heart Failure in the Elderly: Underlying mechanisms and clinical relevance. *Int. J Cardiol*. 2008 Apr 10;125(2):197-202. Epub 2007 Dec 1
98. Sulaiman HM, O'Loughlin C, Daly M, Conlon C, Ledwidge M, McCaffrey D, **McDonald** K. [Need and evolution of need for device therapy in a community heart failure population](#). *Eur J Heart Fail*. 2008 Jun;10(6):601-7. Epub 2008 May 21
99. McDonagh TA, **McDonald** K, Maisel AS. [Screening for asymptomatic left ventricular dysfunction using B-type natriuretic Peptide](#). *Congest Heart Fail*. 2008 Jul-Aug;14(4 Suppl 1):5-8.
100. Dahlström U, **McDonald** K, Maisel A. [Integration of B-type natriuretic Peptide in heart failure outpatient programs](#). *Congest Heart Fail*. 2008 Jul-Aug;14(4 Suppl 1):9-11.
101. **McDonald** K, Dahlström U, Aspromonte N, Jourdain P, Maisel A, Mueller C, Valle R. [B-type natriuretic Peptide: application in the community](#). *Congest Heart Fail*. 2008 Jul-Aug;14(4 Suppl 1):12-6
102. Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG, Cohen-Solal A, Dahlstrom U, DeMaria A, Di Somma S, Filippatos GS, Fonarow GC, Jourdain P, Komajda M, Liu PP, McDonagh T, **McDonald** K, Mebazaa A, Nieminen MS, Peacock WF, Tubaro M, Valle R, Vanderhyden M, Yancy CW, Zannad F, Braunwald E. [State of the art: using natriuretic peptide levels in clinical practice](#). *Eur J Heart Fail*. 2008 Sep;10(9):824-39. Epub 2008 Aug 29.
103. Mak G, Murphy NF, Ali A, Walsh A, O'Loughlin C, Conlon C, McCaffrey D, Ledwidge M, **McDonald** K. [Multiple neurohumoral modulating agents in systolic dysfunction heart failure: are we lowering blood pressure too much?](#) *J Card Fail*. 2008 Sep;14(7):555-60. Epub 2008 May 27.
104. Mak G, Murphy NF, **McDonald** K. Anaemia in heart failure; to treat or not to treat. *Curr Treat Options Cardiovasc Med*. 2008 Dec;10(6):455-64.PMID: 19026176
105. Mak G, Ryder M, Murphy NF, O'Loughlin C, McCaffrey D, Ledwidge M, **McDonald** K. [Diagnosis of new onset heart failure in the community: the importance of a shared-care approach and judicious use of BNP](#). *Ir J Med Sci*. 2008 Sep;177(3):197-203. Epub 2008 Jul 17.
106. **McDonald** K. [Prevalence of heart failure: a reflection of the good and the bad of modern cardiovascular care](#). *Rev Esp Cardiol*. 2008 Oct;61(10):1010-2. No abstract available.



107. Mak G, Murphy NF, **McDonald** K. [Anemia in heart failure: to treat or not to treat?](#) Curr Treat Options Cardiovasc Med. 2008 Dec;10(6):455-64

108. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Murphy NF, Conlon C, Patle A, Donnelly SC, **McDonald** K. [Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover](#). Eur J Heart Fail. 2009 Feb;11(2):191-7. PubMed PMID: 19168518
109. Mockler M, O'Loughlin C, Murphy N, Ryder M, Conlon C, **McDonald** KM, Ledwidge MT. Causes and consequences of non-persistence with heart failure medication. Am J Cardiol. 2009 Mar 15;103(6):834-8.
110. O'Leary N, Murphy NF, O'Loughlin C, Tiernan E, **McDonald** K. [A comparative study of the palliative care needs of heart failure and cancer patients](#). Eur J Heart Fail. 2009 Apr;11(4):406-12. Epub 2009 Feb 5
111. Phelan D, Smyth L, Ryder M, Murphy N, O'Loughlin C, Conlon C, Ledwidge M, **McDonald** K. [Can we reduce preventable heart failure readmissions in patients enrolled in a Disease Management Programme?](#) Ir J Med Sci. 2009 Jun;178(2):167-71. Epub 2009 May 1
112. Mak GJ, Ledwidge MT, Watson CJ, Phelan DM, Dawkins IR, Murphy NF, Patle AK, Baugh JA, **McDonald** KM. [Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone](#). J Am Coll Cardiol. 2009 Oct 27;54(18):1674-82. PubMed PMID: 19850207.
113. Dickstein K, Bogale N, Priori S, Auricchio A, Cleland JG, Gitt A, Limbourg T, Linde C, van Veldhuisen DJ, Brugada J. [The European cardiac resynchronization therapy survey](#). Eur Heart J. 2009 Oct;30(20):2450-60. Epub 2009 Aug 31. (National coordinator: **McDonald** KM)
114. O'Loughlin C, Murphy NF, Conlon C, O'Donovan A, Ledwidge M, **McDonald** K. [Quality of life predicts outcome in a heart failure disease management program](#). Int J Cardiol. 2010 Feb 18;139(1):60-7. Epub 2008 Oct 12.
115. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. [Ivabradine and outcomes in chronic heart failure \(SHIFT\): a randomised placebo-controlled study](#). SHIFT Investigators. Lancet. 2010 Sep 11;376(9744):875-85.
116. Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. [Heart rate as a risk factor in chronic heart failure \(SHIFT\): the association between heart rate and outcomes in a randomised placebo-controlled trial](#). Lancet. 2010 Sep 11;376(9744):886
117. O'Neill AC, McDermott S, Ridge CA, **McDonald** K, Keane D, Dodd JD. Uncharted waters: rare and unclassified cardiomyopathies characterized on cardiac magnetic resonance imaging. Insights Imaging. 2010 Nov; 1(5-6):293-308. Epub 2010 Oct 19. PubMed PMID: 22347924
118. Arnous S, Murphy NF, Pyne-Daly P, Nawoor Z, Keane D, Ledwidge M, **McDonald** K. Clinical and psychological impact of prophylactic implantable cardioverter-defibrillators in a community heart failure population. Ir J Med Sci. 2010 Dec 14.

119. [McDonald KM. Disease Management Programs for Heart Failure. Current Treatments in Cardiovascular Medicine. Curr Treat Options Cardiovasc Med. 2010 Dec;12\(6\):578-86.](#)
120. [Watson CJ, Ledwidge MT, Phelan D, Collier P, Byrne JC, Dunn MJ, McDonald KM, Baugh JA.](#) Proteomic analysis of coronary sinus serum reveals leucine-rich  $\alpha$ 2-glycoprotein as a novel biomarker of ventricular dysfunction and heart failure. [Circ Heart Fail.](#) 2011 Mar;4(2):188-97. PubMed PMID: 21282491
121. [Conlon CM, Dawkins I, O'Loughlin C, Gibson D, Kelleher CC, Ledwidge M, McDonald K.](#) B-type natriuretic peptide measurement in primary care; magnitude of associations with cardiovascular risk factors and their therapies. Observations from the STOP-HF (St. Vincent's Screening TO Prevent Heart Failure) study. [Clin Chem Lab Med.](#) 2011 Apr;49(4):719-28. Epub 2011 Jan 31.
122. [Jan A, Murphy NF, O'Loughlin C, Ledwidge M, McDonald K.](#) Profiling B-type natriuretic peptide in a stable heart failure population: a valuable adjunct to care. [Ir J Med Sci.](#) 2011 Jun;180(2):355-62. Epub 2011 Mar 3.
123. [Bermingham M, O'Callaghan E, Dawkins I, Miwa S, Samsudin S, McDonald K, Ledwidge M.](#) Are beta2-agonists responsible for increased mortality in heart failure? [Eur J Heart Fail.](#) 2011 Aug;13(8):885-91.
124. [Ali M, McDonald K.](#) Very late bare-metal stent thrombosis, rare but stormy! [J Invasive Cardiol.](#) 2011 Aug;23(8):E208-10.
125. [Bermingham M, Hayden J, Dawkins I, Miwa S, Gibson D, McDonald K, Ledwidge M.](#) Prospective analysis of LDL-C goal achievement and self-reported medication adherence among statin users in primary care. [Clin Ther.](#) 2011 Sep;33(9):1180-1189. PubMed PMID: 21840055.
126. [Arnous S, Killeen RP, Martos R, Quinn M, McDonald K, Dodd JD.](#) Quantification of mitral regurgitation on cardiac computed tomography: comparison with qualitative and quantitative echocardiographic parameters. [J Comput Assist Tomogr.](#) 2011 Sep-Oct;35(5):625-30. PubMed PMID 21926860
127. [Collier P, Watson CJ, Voon V, Phelan D, Jan A, Mak G, Martos R, Baugh JA, Ledwidge MT, McDonald KM.](#) Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? [Eur J Heart Fail.](#) 2011 Oct;13(10):1087-95. PubMed PMID: 21719449.
128. [Abulhul E, McDonald KM, Martos R, Phelan D, Spiers JP, Hennessy M, Baugh J, Watson C, O'Loughlin C, Ledwidge MT.](#) Long-Term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation and B-type natriuretic peptide. [Clin. Ther.](#) 2011 Dec 7. PubMed PMID: 22154198
129. [Murtagh G, Dawkins IR, O'Connell R, Badabhagn M, Patel A, Tallon E, O'Hanlon R, Ledwidge MT, McDonald KM.](#) Screening to Prevent Heart Failure (STOP-HF): Expanding the focus beyond asymptomatic left ventricular systolic dysfunction. [European Journal of Heart Failure.](#) 2012 May;14(5):480-6. Epub 2012 Mar 13. PubMed PMID: 22416086.

130. Ryder M, Beattie JM, O'Hanlon R, **McDonald** K. Multidisciplinary heart failure management and end of life care. *Curr Opin Support Palliat Care*. 2011 Dec; 5(4): 317-21. PubMed PMID: 22037275
131. Collier P, Watson CJ, van Es MH; Phelan D, McGorrian C; Tolan M, Ledwidge MT, **McDonald** KM; Baugh. Getting to the heart of cardiac remodelling; how collagen subtypes may contribute to phenotype. *Journal of Molecular and Cellular Cardiology*. 2012 Jan;52(1):148-53. PubMed PMID: 22008391
132. P. Collier; M. Ledwidge; K. **McDonald** Diagnostics and therapeutic interventions in myocardial interstitial disease, a previously neglected pathology; *Aug;105(8):721-4*. Epub 2012 May 29 PMID: 22647762
133. M. Ledwidge; L. Lawlor; B.Travers; N. Edwards; D.Kelly; V.Voon; K. **McDonald**; Can individualized weight monitoring using the HeartPhone algorithm improve sensitivity for clinical deterioration of heart failure?; *European Journal of Heart Failure*. 2013 Apr;15(4):447-55. Epub 2012 Nov 29 PubMed PMID: 23204211
134. Voon V, Murtagh G, Ledwidge M, **McDonald** K. Developments in home monitoring in heart failure. *Hosp Cardiol Euro* 2012;Winter:21-23
135. Collier P, Watson CJ, Waterhouse D, Dawkins I, Petle A, Horgan S, Conlon C, O'Hanlon R, Baugh JA, Ledwidge MT, **McDonald** KM. (2012). Progression of Left Atrial Volume Index in a Population At Risk for Heart Failure: A Sub-Study of the STOP-HF (St. Vincent's Screening TO Prevent Heart Failure) Trial. *Eur J Heart Fail*. 14(9):957-64.
136. Watson CJ, Phelan D, Xu M, Collier P, Neary R, Smolenski A, Ledwidge M, **McDonald** K, Baugh J. (2012). Mechanical stretch up-regulates the B-type natriuretic peptide system in human cardiac fibroblasts: A possible defense against transforming growth factor- $\beta$  mediated fibrosis. *Fibrogenesis & Tissue Repair*. 7;5(1):9.
137. Phelan D, Watson CJ, Martos R, Collier P, Patle A, Dawkins I, Donnelly S, Ledwidge M, Baugh J, **McDonald** K. (2012) Modest Elevation in BNP in Asymptomatic Hypertensive Patients Reflects Sub-Clinical Cardiac Remodeling, Inflammation and Extracellular Matrix Changes. *PLoS One*. 7(11).
138. Glezeva N, Collier P, Voon V, Ledwidge M, **McDonald** K, Watson C, Baugh J. Attenuation of monocyte chemotaxis - a novel anti-inflammatory mechanism of action for the cardio-protective hormone B-type Natriuretic Peptide. *J Cardiovasc Transl Res* 2013;6:545-57.

139. Ledwidge M, Gallagher J, Conlon C, Tallon E, O'Connell E, Dawkins I, Watson C, O'Hanlon R, Bermingham M, Patle A, Badabhagani MR, Murtagh G, Voon V, Tilson L, Barry M, **McDonald L**, Maurer B, **McDonald KM**. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. *JAMA* 2013;310(1):66-74.
140. Watson CJ, Collier P, Tea I, Neary R, Watson J, Robinson C, Phelan D, Ledwidge M, **McDonald K**, McCann A, Sharaf O, Baugh J. 2013. Hypoxia-induced epigenetic modifications are associated with cardiac tissue fibrosis and the development of a myofibroblast-like phenotype. *Hum Mol Genet* 2014;23:2176-88.
141. Jan A, Dawkins I, Murphy N, Collier P, Baugh J, Ledwidge M, **McDonald K**, Watson CJ. Associates of an elevated natriuretic peptide level in stable heart failure patients: implications for targeted management. *The Scientific World Journal* 2013;Dec 25:562763.
142. Bermingham M, Shanahan MK, O'Connell E, Dawkins I, Miwa S, O'Hanlon R, Gilmer J, **McDonald K**, Ledwidge M. Aspirin Use In Heart Failure: Is Low Dose Therapy Associated With Mortality And Morbidity Benefits In A Large Community Population? *Circ Heart Fail*. 2014 Feb 3. [Epub ahead of print]
143. Watson CJ, Phelan D, Collier P, Horgan S, Glezeva N, Cooke G, Xu M, Ledwidge M, **McDonald K**, Baugh J. Extracellular matrix sub-types and mechanical stretch impact human cardiac fibroblast responses to transforming growth factor beta. *Connect Tissue Res* 2014;55:248-56.
144. James S, Waterhouse D, **McDonald K**, O'Hanlon R. Dilated cardiomyopathy and progressive familial intrahepatic cholestasis. *BMJ Case Rep* 2014; Mar 20;2014.
145. Bermingham M, Ryder M, Travers B, Edwards N, Lalor L, Kelly D, Gallagher J, O'Hanlon R, **McDonald K**, Ledwidge M. The St Vincent's Potentially Inappropriate Medicines Study: development of a disease-specific consensus list and its evaluation in ambulatory heart failure care. *Eur J Heart Fail* 2014;16:915-22.
146. Moran D, Buckley A, Daly K, Meaney B, Curtin R, O'Neill JO, Colwell N, Mahon N, Murphy N, O'Hanlon R, Daly C, Mc Adam B, **Mc Donald K**, Maher V. Heart rate awareness in patients with chronic stable heart failure. A multi-center observational study. *Int J Cardiol* 2014 Aug 23.
147. Murtagh G, O'Connell J, O'Connell E, Tallon E, Watson C, Gallagher J, Baugh J, Patle A, O'Connell L, Griffin J, O'Hanlon R, Voon V, Ledwidge M, O'Shea D, **McDonald K**. Importance of Risk Factor Management in Diabetic Patients & Reduction in Stage B Heart Failure. *QJM* 2014; DOI:10.1093/qjmed/hcu189
148. Glezeva N, Voon V, Watson CJ, Horgan S, Ledwidge M, **McDonald K**, Baugh J (2014). Exaggerated inflammation and monocytosis associate with diastolic dysfunction in Heart Failure with Preserved Ejection Fraction: evidence of M2 macrophage activation in disease pathogenesis. *J. Card. Fail.* 2015 Feb;21(2):167-77.
149. Glezeva N, Gallagher J, Ledwidge M, O'Donoghue J, **McDonald K**, Chipolombwe J, Watson CJ (2015). Heart failure in sub-Saharan Africa: review of the aetiology of heart failure and the role of point-of-care biomarker diagnostics. *Trop Med Int Health. Trop Med Int Health*. 2015 May;20(5):581-588.

150. Watson CJ, Gupta S, O'Connell E, Thum S, Glezeva N, Fendrich J, Gallagher J, Grote-Levi A, Ledwidge M, **McDonald** K, Thum T (2015). MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. *Eur J Heart Fail*. 2015 Apr;17(4):405-15.
151. Watson CJ, Gallagher J, Ledwidge M, **McDonald** K: Biomarker Testing and Pre-emptive Therapy in Preventing Heart Failure (2015). *Current Cardiovascular Risk reports*, 06/2015: 9(6)
152. **McDonald** KM, Murphy. Predict, Protect, Prevent. Working towards a personalised approach to heart failure prevention (2015). [JACC Heart Fail](#). 2015 Jun;3(6):456-8.
153. Ledwidge MT, O'Connell E, Gallagher J, Tilson L, James S, Voon V, Bermingham M, Tallon E, Watson C, O'Hanlon R, Barry M, **McDonald** K. [Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF \(St Vincent's Screening TO Prevent Heart Failure\) study](#). *Eur J Heart Fail*. 2015 Jul;17(7):672-9.
154. **McDonald** K, Wilkinson M, Ledwidge M. [Role of Monitoring Devices in Preventing Heart Failure Admissions](#). *Curr Heart Fail Rep*. 2015 Aug;12(4):269-75.
155. Watson CJ, Gupta SK, O'Connell E, Thum S, Glezeva N, Fendrich J, Gallagher J, Ledwidge M, Grote-Levi L, **McDonald** K, Thum T. [MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure](#). *Eur J Heart Fail*. 2015 Apr;17(4):405-15.
156. James S, Barton D, O'Connell E, Voon V, Murtagh G, Watson C, Murphy T, Prendiville B, Brennan D, Hensey M, O'Neill L, O'Hanlon R, Waterhouse D, Ledwidge M, Gallagher J, **McDonald** K. [Life expectancy for community-based patients with heart failure from time of diagnosis](#). *Int J Cardiol*. 2015 Jan 15;178:268-74.
157. Glezeva N, Voon V, Watson C, Horgan S, **McDonald** K, Ledwidge M, Baugh J. [Exaggerated inflammation and monocytosis associate with diastolic dysfunction in heart failure with preserved ejection fraction: evidence of M2 macrophage activation in disease pathogenesis](#). *J Card Fail*. 2015 Feb;21(2):167-77.
158. **McDonald** K, Murphy T. [Predict, Protect, Prevent: Working Toward a Personalized Approach to Heart Failure Prevention](#). *JACC Heart Fail*. 2015 Jun;3(6):456-8. doi: 10.1016/j.jchf.2015.01.011. Epub 2015 May 14.
159. Watson CJ, Horgan S, Neary R, Glezeva N, Tea I, Corrigan N, **McDonald** K, Ledwidge M, Baugh J. [Epigenetic Therapy for the Treatment of Hypertension-Induced Cardiac Hypertrophy and Fibrosis](#). *J Cardiovasc Pharmacol Ther*. 2016 Jan;21(1):127-37. doi: 10.1177/1074248415591698. Epub 2015 Jun 30.
160. Ledwidge MT, O'Connell E, Gallagher J, Tilson L, James S, Voon V, Bermingham M, Tallon E, Watson C, O'Hanlon R, Barry M, **McDonald** K. [Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF \(St Vincent's Screening TO Prevent Heart Failure\) study](#). *Eur J Heart Fail*. 2015 Jul;17(7):672-9. doi: 10.1002/ehfj.286.
161. **McDonald** K, Wilkinson M, Ledwidge M. [Role of Monitoring Devices in Preventing Heart Failure Admissions](#). *Curr Heart Fail Rep*. 2015 Aug;12(4):269-75. doi: 10.1007/s11897-015-0262-8. Review.

162. Horgan SJ, Watson CJ, Glezeva N, Collier P, Neary R, Tea IJ, Corrigan N, Ledwidge M, **McDonald K**, Baugh JA. Serum Amyloid P-Component Prevents Cardiac Re-modeling in Hypertensive Heart Disease. J Cardiovasc Transl Res. 2015 Dec;8(9):554-66. doi: 10.1007/s12265-015-9661-1. Epub 2015 Nov 17.
163. Watson C, James S, O'Connell E, Gallagher J, O'Reilly J, Tallon E, Baugh J, O'Connell J, O'Shea D, Ledwidge M, **McDonald K**. Influence of diabetes on natriuretic peptide thresholds in screening for Stage B heart failure. Biomarkers. 2016 Sep;21(6):538-43. doi: 10.3109/1354750X.2016.1160427. Epub 2016 Apr 6
164. Murtagh G, Lyons T, O'Connell E, Ballot J, Geraghty L, Fennelly D, Gullo G, Ledwidge M, Crown J, Gallagher J, Watson C, **McDonald KM**, Walshe JM. Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up. Breast Cancer Res Treat. 2016 Apr;15 (3):501-6.
165. Maisel AS, Wettersten N, van Veldhuisen DJ, Mueller C, Filippatos G, Nowak R, Hogan C, Kontos MC, Cannon CM, Müller GA, Birkhahn R, Clopton P, Taub P, Vilke GM, **McDonald K**, Mahon N, Nuñez J, Briguori C, Passino C, Murray PT. Neutrophil Gelatinase-Associated Lipocalin for Acute Kidney Injury During Acute Heart Failure Hospitalizations: The AKINESIS Study. J Am Coll Cardiol. 2016 Sep 27;68
166. [Murphy TM](#), [Waterhouse DE](#), [James S](#), [Casey C](#), [Fitzgerald E](#), [O'Connell E](#), [Watson C](#), [Gallagher J](#), [Ledwidge M](#), **McDonald K**. A comparison of HFrEF vs HFpEF's clinical workload and cost in the first year following hospitalization and enrollment in a disease management program. International Journal of Cardiology. 2016 Dec 23. [Epub ahead of print]
167. **McDonald, K.** and M. Wilkinson, Evolving Use of Natriuretic Peptides as Part of strategies for Heart Failure Prevention. Clinical Chemistry, 2017. 63(1): p. 66-72.